Synonym
Oxepinac; Oxepinaco; Oxepinacum
IUPAC/Chemical Name
6,11-Dihydro-11-oxodibenz(b,e)oxepin-3-acetic acid
InChi Key
PYIHCGFQQSKYBO-UHFFFAOYSA-N
InChi Code
InChI=1S/C16H12O4/c17-15(18)8-10-5-6-13-14(7-10)20-9-11-3-1-2-4-12(11)16(13)19/h1-7H,8-9H2,(H,17,18)
SMILES Code
O=C(O)CC1=CC=C2C(OCC3=CC=CC=C3C2=O)=C1
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>3 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
Preparing Stock Solutions
The following data is based on the
product
molecular weight
268.27
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
1: Kojima H, Hashizume T, Chiba T, Tanaka M, Kasai Y, Kasahara A. General pharmacology of oxepinac. Arzneimittelforschung. 1978;28(3):439-45. PubMed PMID: 580753.
2: Arauchi T, Watanabe T, Nakashima K, Matsuhashi K, Morita H, Akimoto T. Teratogenicity study of oxepinac in mice and rabbits. Arzneimittelforschung. 1978;28(3):451-5. PubMed PMID: 580755.
3: Nomura M, Onodera T, Kato M, Yamada A, Ogawa H, Akimoto T. Acute, subacute and chronic toxicity of oxepinac. Arzneimittelforschung. 1978;28(3):445-51. PubMed PMID: 580754.
4: Hakusui H, Suzuki W, Takegoshi T, Saito T, Sano M. Studies on pharmacokinetics and biotransformation of oxepinac in mouse, rat, dog and man. Arzneimittelforschung. 1978;28(3):456-61. PubMed PMID: 580756.
5: Sasaki S. Multi-centered clinical evaluation of oxepinac against peripheral arthropathy particularly osteoarthritis. Arzneimittelforschung. 1978;28(3):462-8. PubMed PMID: 350232.
6: Hakusui H, Suzuki W, Sano M. Quantitative analysis of oxepinac in human plasma, urine and saliva by gas chromatography--mass fragmentography. J Chromatogr. 1980 Apr 11;182(1):47-53. PubMed PMID: 7380901.
7: Tsukada W, Tsubokawa M, Masukawa T, Kojima H, Kasahara A. Pharmacological study of 6,11-dihydro-11-oxodibenz[b,e]oxepin-3-acetic acid (oxepinac): a new antiinflammatory drug. Arzneimittelforschung. 1978;28(3):428-38. PubMed PMID: 580752.
8: Tagawa H, Kubo S. Nonsteroidal antiinflammatory agents. V. Photolysis of 6,11-dihydro-11-oxodibenz[b,e]oxepin-3-acetic acid. Chem Pharm Bull (Tokyo). 1984 Aug;32(8):3047-52. PubMed PMID: 6518586.
